All In Biotech

Drug Trial Radar · NCT01318499

Nepafenac 0.3% Two Study

Clinical Evaluation of Nepafenac Ophthalmic Suspension, 0.3% Compared to Nepafenac Ophthalmic Suspension 0.1% and Vehicle for Prevention and Treatment of Ocular Inflammation and Pain Associated With Cataract Surgery

Last checked: Nov 20, 2026Latest source record: Dec 17, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 1,342 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,342

Actual

Start

Mar 2011

Primary completion

Sep 2011

Study completion Sep 2011

Sponsor

Lead sponsor
Alcon ResearchIndustry
Sponsor type
Industry
First posted
Mar 18, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to assess the safety and efficacy of Nepafenac Ophthalmic Suspension, 0.3% for the prevention and treatment of inflammation (swelling and redness) and pain in the eye after cataract extraction.

Conditions

  • Cataract

Interventions

  • Nepafenac Ophthalmic Suspension, 0.3%Drug

    Nepafenac Ophthalmic Suspension, 0.3%, one drop in affected eye once daily, for 16 days. An additional drop was administered between 30-120 minutes prior to surgery.

  • Nepafenac Ophthalmic Suspension, 0.1%Drug

    Nepafenac Ophthalmic Suspension, 0.1%, one drop in affected eye once daily, for 16 days. An additional drop was administered between 30-120 minutes prior to surgery.

  • Nepafenac Vehicle 0.3%Other

    Nepafenac Vehicle 0.3%, one drop in affected eye once daily, for 16 days. An additional drop was administered between 30-120 minutes prior to surgery.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Patients Cured at Day 14, Nepafenac 0.3% vs. Nepafenac Vehicle 0.3%Time frame: Day 14 postoperative

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Contact Alcon Call Center for Trial Locations

    Fort Worth, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.